Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.83 |
| ▸ | TYK2 | P29597 | 2/20 | 0.82 |
| ▸ | JAK1 | P23458 | 12/20 | 0.79 |
| ▸ | JAK3 | P52333 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238494 | 0.91 | JAK2 (1.00) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL2243221 | 0.90 | JAK2 (1.00) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL2241762 | 0.89 | JAK2 (1.00) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL2238034 | 0.89 | JAK2 (0.85) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL2237921 | 0.88 | JAK2 (1.00) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL2240386 | 0.88 | JAK2 (0.84) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL2237152 | 0.88 | JAK2 (1.00) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL2238754 | 0.88 | JAK2 (1.00) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL2235909 | 0.87 | JAK2 (1.00) | JAK2TYK2JAK1JAK3 | |
| SCHEMBL253852 | 0.87 | JAK2 (1.00) | JAK2TYK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088764-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2012-01-03 | — | — | US | disclosed |
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | JAK2 9/4885TYK2 52/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.